Brokerages expect that Orthopediatrics Corp (NASDAQ:KIDS) will announce earnings of ($0.18) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Orthopediatrics’ earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.24). Orthopediatrics posted earnings of ($3.93) per share during the same quarter last year, which would indicate a positive year over year growth rate of 95.4%. The company is scheduled to issue its next quarterly earnings report on Wednesday, March 6th.
On average, analysts expect that Orthopediatrics will report full year earnings of ($0.95) per share for the current year, with EPS estimates ranging from ($1.01) to ($0.90). For the next year, analysts expect that the business will post earnings of ($0.44) per share, with EPS estimates ranging from ($0.53) to ($0.38). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Orthopediatrics.
Several equities analysts have commented on the company. Zacks Investment Research raised Orthopediatrics from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a research report on Wednesday, January 2nd. BidaskClub raised Orthopediatrics from a “hold” rating to a “buy” rating in a research report on Thursday, December 20th. Finally, BTIG Research increased their price target on Orthopediatrics to $37.00 and gave the stock a “buy” rating in a research report on Wednesday, January 2nd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Orthopediatrics presently has a consensus rating of “Buy” and an average target price of $35.00.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Royce & Associates LP grew its position in shares of Orthopediatrics by 7.2% during the 4th quarter. Royce & Associates LP now owns 193,500 shares of the company’s stock worth $6,749,000 after buying an additional 13,000 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Orthopediatrics by 14.3% during the 4th quarter. Bank of New York Mellon Corp now owns 21,500 shares of the company’s stock worth $750,000 after buying an additional 2,697 shares in the last quarter. BlackRock Inc. grew its position in shares of Orthopediatrics by 12.4% during the 4th quarter. BlackRock Inc. now owns 455,657 shares of the company’s stock worth $15,894,000 after buying an additional 50,179 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Orthopediatrics by 48.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 18,100 shares of the company’s stock worth $631,000 after buying an additional 5,900 shares in the last quarter. Finally, Rhumbline Advisers grew its position in shares of Orthopediatrics by 55.5% during the 4th quarter. Rhumbline Advisers now owns 8,770 shares of the company’s stock worth $306,000 after buying an additional 3,129 shares in the last quarter. 43.31% of the stock is currently owned by institutional investors and hedge funds.
Orthopediatrics stock traded up $1.19 during mid-day trading on Monday, hitting $37.33. The company’s stock had a trading volume of 104,400 shares, compared to its average volume of 49,589. The company has a market capitalization of $463.01 million, a PE ratio of -6.55 and a beta of 0.11. The company has a quick ratio of 3.23, a current ratio of 5.67 and a debt-to-equity ratio of 0.62. Orthopediatrics has a one year low of $14.00 and a one year high of $39.81.
Orthopediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.
Further Reading: Price-Sales Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.